EMG
LCTX icon

ETF Managers Group’s Lineage Cell Therapeutics LCTX Stock Holding History

ETF Managers Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$478K Sell
318,596
-35,395
-10% -$49.4K 0.02% 459
2022
Q4 		$414K Buy
353,991
+24,165
+7% +$30.5K 0.02% 395
2022
Q3 		$373K Buy
329,826
+24,892
+8% +$36.6K 0.01% 525
2022
Q2 		$491K Buy
304,934
+112,307
+58% +$148K 0.01% 497
2022
Q1 		$289K Sell
192,627
-15,108
-7% -$23.4K 0.01% 544
2021
Q4 		$519K Buy
+207,735
New +$486K 0.01% 515

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ETF Managers Group's LCTX Position: Q1 2023 in Review

ETF Managers Group reduced its Lineage Cell Therapeutics (LCTX) stake by 10% in Q1 2023, selling an estimated $49.4K and leaving 318,596 shares worth $478K. The position accounts for 0.02% of the portfolio, ranked #459.

ETF Managers Group first reported a position in LCTX in Q4 2021 and has held it in 6 quarters since. The position peaked at $519K in Q4 2021. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2023.

  • ETF Managers Group held 318,596 shares of Lineage Cell Therapeutics worth $478K as of Q1 2023.
  • ETF Managers Group sold 35,395 Lineage Cell Therapeutics shares in Q1 2023, an estimated $49.4K.
  • Lineage Cell Therapeutics made up 0.02% of ETF Managers Group's portfolio in Q1 2023, its #459 holding.
  • ETF Managers Group first reported a position in Lineage Cell Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • ETF Managers Group's Lineage Cell Therapeutics position peaked at $519K in Q4 2021.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.